Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Quantitative in vivo analyses reveal a complex pharmacogenomic landscape in lung adenocarcinoma

ABSTRACT: The lack of knowledge about the relationship between tumor genotypes and therapeutic responses remains one of the most important gaps in enabling the effective use of cancer therapies. Here, we couple a multiplexed and quantitative platform with robust statistical methods to enable pharmacogenomic mapping of lung cancer treatment responses in vivo. We uncover a surprisingly complex map of genotype-specific therapeutic responses, with over 20% of possible interactions showing significant resistance or sensitivity. We validate one of these interactions - the resistance of Keap1 mutant tumors to platinum therapy - using a large patient response dataset. Our results highlight the importance of understanding the genetic determinants of treatment responses in the development of precision therapies and define a strategy to identify such determinants.

ORGANISM(S): Mus musculus

PROVIDER: GSE146448 | GEO | 2021/03/05

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)

Project description:Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)

| PRJNA215007 | ENA

Pharmacogenomic interactions in Glioblastoma cell line models

Project description:Pharmacogenomic interactions in Glioblastoma cell line models

| PRJNA526264 | ENA

Pharmacogenomic interactions in Glioblastoma cell line models

Project description:Pharmacogenomic interactions in Glioblastoma cell line models

| PRJNA526265 | ENA

Affymetrix SNP array data for pharmacogenomic profile of Benzidazole adverse reactions.

Project description:Search for SNPs associated with the pharmacogenomic profile of Benzidazole adverse reactions in Chagas Disease Homo sapiens patients.

2021-03-31 | GSE154421 | GEO

Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)

Project description:<p>This is a prospective, multicenter, randomized, open-label, parallel-group study to evaluate pharmacogenomic responses to antihypertensives. The primary aim of this study is to identify the genetic determinants of antihypertensive and adverse metabolic responses focused on two preferred and pharmacodynamically contrasting drugs, a beta-blocker (atenolol) and a thiazide diuretic (HCTZ) given initially as monotherapy, and subsequently in combination, to 768 individuals with uncomplicated hypertension. This includes assessment of genetic associations with: antihypertensive responses to monotherapy, addition of a second drug to monotherapy, and combination therapy; and adverse metabolic responses to mono and combination therapy. High quality phenotype data, including both home and ambulatory measures of blood pressure response, and lipid and insulin sensitivity measures of adverse metabolic responses were collected. DNA samples were plated into 96-well plates and included a 2% sample replication for QC and a Caucasian parent-child CEPH trio from the HapMap project to check for Mendelian transmission of alleles. Genotypes were determined with the Illumina HumanOmni1-Quad and HumanCVD BeadChip.</p>

| phs000649 | dbGaP

Pharmacogenomic characterization of the MDM2 inhibitor MI-773 reveals candidate tumours and predictive biomarkers

Project description:MI-773 is a recently developed small-molecule inhibitor of the Mouse Double Minute 2 (MDM2) proto-oncogene. Here we report an integrative pharmacogenomic study to gain further insights into the therapeutic potential of the compound.

2021-10-27 | GSE152529 | GEO

Pharmacogenomic eQTL mediated by androgen receptor modulators

Project description:Endocrine therapy is the most important treatment modality of breast cancer patients whose tumors express the estrogen receptor  (ER). The androgen receptor (AR) is also expressed in the vast majority (80-90%) of ER-positive tumors. However, AR-targeting drugs are not used in clinical practice, but have been evaluated in multiple trials and preclinical studies. We performed a genome-wide study to identify genetic context-dependent AR signaling induced by either AR agonist (dihydrotestosterone [DHT]), or AR antagonist (enzalutamide [Enz]), known as pharmacogenomic expression quantitative expression loci (PGx-eQTLs), utilizing a previously well characterized lymphoblastic cell line panel.

2024-01-01 | GSE245417 | GEO

Genome-Wide CRISPR Screen Identifies Pharmacogenomic Determinants of Blinatumomab Resistance in Acute Lymphoblastic Leukemia [RNA-seq]

Project description:Blinatumomab is an efficacious immunotherapeutic agent in B-cell acute lymphoblastic leukemia (ALL). However, pharmacogenomic basis of leukemia response to blinatumomab is unclear. Using genome-wide CRISPR, we comprehensively identified leukemia intrinsic factors of blinatumomab sensitivity, i.e., the loss of CD58 as a top driver for resistance, in addition to CD19. CD58 expression varied across 20 ALL moleuclar subtypes, with marked downregulation linked to PAX5 P80R mutation in leukemia. Genome editing confirmed the effects of this mutation on CD58 expression and blinatumomab sensitivity in B-ALL, with validation in patient leukemic blasts. We described a PAX5-driven enhancer at the CD58 locus, which was disrupted by PAX5 P80R. Without CD58 in B-ALL, blinatumomab-induced T cell activation was abolished with transcriptomic/ epigenomic reprogramming. Finally, we screened 1,639 transcription factor genes to systematically identify regulators of CD58/CD19 expression. In conclusion, we identified novel genetic mechanisms of blinatumomab resistance in B-ALL, suggesting strategies for genomics-guided treatment individualization.

2022-12-21 | GSE201831 | GEO

Genome-Wide CRISPR Screen Identifies Pharmacogenomic Determinants of Blinatumomab Resistance in Acute Lymphoblastic Leukemia [ChIP-seq]

2022-12-21 | GSE202082 | GEO

Genome-Wide CRISPR Screen Identifies Pharmacogenomic Determinants of Blinatumomab Resistance in Acute Lymphoblastic Leukemia [ATAC-seq]

2022-12-21 | GSE202081 | GEO